Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LOVENOX (PRESERVATIVE FREE) vs ENOXAPARIN SODIUM (PRESERVATIVE FREE)
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Low molecular weight heparin (LMWH) that potentiates antithrombin III, accelerating inactivation of factor Xa and thrombin.
Enoxaparin binds to antithrombin III (ATIII), accelerating its inhibition of coagulation factors Xa and IIa (thrombin). Its anti-factor Xa to anti-factor IIa activity ratio is approximately 3.6:1.
Prophylaxis of deep vein thrombosis (DVT) in abdominal surgery, hip replacement, knee replacement, or medical patients at risk,Treatment of DVT with or without pulmonary embolism,Prophylaxis of ischemic complications in unstable angina or non-Q-wave myocardial infarction,Treatment of acute ST-segment elevation myocardial infarction (STEMI) managed medically or with percutaneous coronary intervention
Prophylaxis of deep vein thrombosis (DVT) in abdominal or hip/knee replacement surgery,Prophylaxis of DVT in medical patients at risk for thromboembolic complications,Treatment of acute DVT with or without pulmonary embolism,Treatment of unstable angina and non-ST-segment elevation myocardial infarction (NSTEMI) with aspirin,Treatment of acute ST-segment elevation myocardial infarction (STEMI) managed medically or with percutaneous coronary intervention
1 mg/kg subcutaneously every 12 hours or 1.5 mg/kg subcutaneously once daily.
1 mg/kg subcutaneously every 12 hours or 1.5 mg/kg subcutaneously once daily. For prophylaxis: 40 mg subcutaneously once daily or 30 mg subcutaneously every 12 hours.
Terminal half-life: 3-5 hours after subcutaneous injection; prolonged in renal impairment (up to 8-10 hours with Cr Cl <30 m L/min).
Terminal elimination half-life is 4.5 hours after subcutaneous administration based on anti-Factor Xa activity; prolonged to 6-7 hours in renal impairment (Cr Cl <30 m L/min).
Metabolized primarily by desulfation and depolymerization in the liver via heparinases; renally eliminated as unchanged drug and metabolites.
Enoxaparin is primarily metabolized in the liver via desulfation and depolymerization, with some renal clearance. It does not rely on cytochrome P450 enzymes.
Renal: 40-60% as unchanged drug and low molecular weight fragments via glomerular filtration; biliary/fecal: negligible.
Renal excretion of anti-Factor Xa activity accounts for approximately 40% of total clearance; a small fraction undergoes biliary/fecal elimination (<10%).
Approximately 90% bound to antithrombin III (minor binding to other plasma proteins).
Approximately 92-95% bound to antithrombin III (ATIII) and other plasma proteins.
4-7 L (0.06-0.1 L/kg) – predominantly confined to intravascular space.
0.10-0.13 L/kg; confined primarily to intravascular space, indicating limited extravascular distribution.
Subcutaneous: ~90-100% (almost complete absorption).
Subcutaneous: Approximately 92-100% absorbed; intravenous administration yields 100% bioavailability.
For Cr Cl <30 m L/min: reduce dose to 1 mg/kg subcutaneously once daily. For Cr Cl 30-50 m L/min: no dose adjustment required, but monitor carefully.
For Cr Cl <30 m L/min: reduce dose to 1 mg/kg subcutaneously once daily for treatment; for prophylaxis: 30 mg subcutaneously once daily. Not recommended if Cr Cl <15 m L/min.
No specific dose adjustment recommended for hepatic impairment; caution in severe hepatic impairment due to increased bleeding risk.
No specific dose adjustment guidelines for hepatic impairment; use with caution in severe hepatic impairment due to increased bleeding risk.
Neonates: 1.5 mg/kg subcutaneously every 12 hours. Infants and children: 1 mg/kg subcutaneously every 12 hours.
Dose based on age: neonates and infants <2 months: 1.5 mg/kg subcutaneously every 12 hours; children ≥2 months: 1 mg/kg subcutaneously every 12 hours. For prophylaxis: 0.5 mg/kg subcutaneously every 12 hours.
No specific dose adjustment, but increased risk of bleeding; monitor renal function and adjust dose if Cr Cl <30 m L/min.
Increased risk of bleeding, especially in elderly ≥75 years; consider dose reduction and monitor renal function and anti-Xa levels. For treatment in elderly ≥75 years: 1 mg/kg subcutaneously every 12 hours; no routine dose reduction but caution advised.
Spinal/epidural hematomas, including subsequent paralysis, may occur in patients anticoagulated with LMWH or heparinoids who receive neuraxial anesthesia or undergo spinal puncture. Risk increased by use of indwelling epidural catheters, concomitant use of drugs affecting hemostasis, history of traumatic or repeated epidural/spinal punctures, or history of spinal deformity or surgery.
Spinal/epidural hematomas may occur in patients receiving enoxaparin who are undergoing neuraxial anesthesia or spinal puncture, resulting in long-term or permanent paralysis. Risk is increased by use of indwelling epidural catheters, concomitant use of other anticoagulants, or history of spinal surgery/deformity. Monitor for signs of neurological impairment and manage emergently.
Risk of bleeding; thrombocytopenia, including heparin-induced thrombocytopenia (HIT); use in renal impairment (reduce dose if Cr Cl <30 m L/min); elderly patients (increased bleeding risk); pregnancy (category B); use with caution in patients with history of heparin-induced thrombocytopenia; monitor for signs of bleeding.
Risk of spinal/epidural hematoma with neuraxial procedures,Increased bleeding risk, especially in patients with renal impairment, thrombocytopenia, or concurrent use of anticoagulants/antiplatelets,Heparin-induced thrombocytopenia (HIT) possible; monitor platelet counts,Use with caution in patients with bleeding disorders, uncontrolled hypertension, or recent surgery,Not interchangeable with other heparins (unit-for-unit)
Active major bleeding; history of heparin-induced thrombocytopenia (HIT) or heparin-induced thrombocytopenia with thrombosis (HITT); hypersensitivity to heparin or pork products; not recommended for use in patients with prosthetic heart valves, especially pregnant women (risk of valve thrombosis).
Active major bleeding,History of immune-mediated heparin-induced thrombocytopenia (HIT) within 100 days,Known hypersensitivity to enoxaparin, heparin, or pork products,Concomitant use with other anticoagulants (except under close monitoring)
No known direct food interactions. However, foods high in vitamin K (e.g., green leafy vegetables, broccoli, Brussels sprouts) may theoretically affect coagulation but are not a concern with LMWH. Avoid or limit alcohol consumption due to increased bleeding risk.
No specific food restrictions. Avoid excessive consumption of alcohol (may increase bleeding risk). Maintain adequate vitamin K intake, but avoid sudden large changes.
Low risk of teratogenicity; enoxaparin does not cross the placenta and is not associated with fetal malformations. In the first trimester, risk of teratogenicity is minimal but consider anticoagulation alternatives if VTE prophylaxis needed; second and third trimesters: no known teratogenic risk, but increased risk of maternal bleeding and placental abruption; perinatal: risk of neonatal bleeding if administered near delivery.
Enoxaparin does not cross the placenta and is considered low risk for teratogenicity. No increased risk of congenital anomalies has been reported in humans. First trimester: no known teratogenic effects. Second trimester: no known fetal harm. Third trimester: risk of maternal hemorrhage, which may indirectly affect fetus; use with caution.
Excreted into breast milk in negligible amounts; M/P ratio not clinically significant; compatible with breastfeeding; no adverse effects in nursing infants reported.
Enoxaparin is excreted into breast milk in negligible amounts. The milk-to-plasma ratio is approximately 0.04. It is considered compatible with breastfeeding due to poor oral bioavailability in the infant. No adverse effects reported.
Dose adjustment not typically required based on pregnancy alone; however, increased plasma volume and renal clearance may necessitate dose escalation; monitor anti-Xa levels and adjust dose to maintain target range (e.g., 0.5-1.0 IU/m L for twice-daily prophylaxis); avoid dose adjustment for physiological anemia.
Pregnancy increases plasma volume and renal clearance, leading to decreased peak anti-Xa levels and half-life. Dose adjustments may be needed to maintain therapeutic levels, especially in the third trimester. Weight-based dosing is recommended and may require upward titration. Anti-Xa monitoring is advised to guide dose adjustments. No standard fixed dose adjustment; individualize based on anti-Xa levels and clinical response.
Lovenox (enoxaparin) is a low molecular weight heparin (LMWH) that does not require routine monitoring of anti-Xa levels except in special populations (e.g., renal impairment, obesity, pregnancy). Use with caution in patients with severe renal impairment (Cr Cl <30 m L/min) as enoxaparin accumulates; consider dose reduction or alternative agent. Protamine sulfate can partially reverse anticoagulation (1 mg protamine per 1 mg enoxaparin). Risk of spinal/epidural hematoma with neuraxial anesthesia or spinal puncture; remove catheter at least 12 hours after last prophylactic dose and 24 hours after last treatment dose. Contraindicated in active major bleeding, history of heparin-induced thrombocytopenia (HIT), or hypersensitivity to heparin products. Calculate dose based on actual body weight, not ideal body weight, for treatment indications.
Enoxaparin is a low molecular weight heparin (LMWH) preferred over unfractionated heparin for VTE prophylaxis due to predictable pharmacokinetics and no need for routine a PTT monitoring. Adjust dose for renal impairment (Cr Cl <30 m L/min). Protamine sulfate partially reverses (about 60%) its anticoagulant effect. Monitor for signs of bleeding, especially in elderly, low body weight (<45 kg), or those on antiplatelet agents. Avoid intramuscular injections. Spinal/epidural hematoma risk with neuraxial anesthesia; remove catheter at least 12 hours after last dose (24 hours if therapeutic dose).
Do not stop taking or change the dose without consulting your healthcare provider.,Report any signs of bleeding (unusual bruising, prolonged bleeding, blood in urine/stool, coughing up blood, bleeding gums) or injection site reactions (pain, redness, swelling).,Avoid aspirin, NSAIDs (ibuprofen, naproxen), or other blood thinners unless prescribed by your doctor.,Inform your doctor if you are pregnant, plan to become pregnant, or are breastfeeding.,If you have an epidural or spinal tap, inform your doctor that you are taking enoxaparin.,Store at room temperature; do not freeze. Use prefilled syringes only once and dispose of properly.,If you miss a dose, take it as soon as possible unless it is almost time for the next dose; do not double the dose.
Take exactly as prescribed; do not skip doses.,Inject subcutaneously in the fatty tissue of the abdomen, alternating sides.,Do not rub the injection site after administration.,Report any unusual bleeding or bruising, blood in urine or stool, or coughing up blood.,Avoid aspirin or NSAIDs unless directed by your doctor.,Seek immediate medical attention for severe headache, back pain, or neurological symptoms (signs of spinal hematoma).,Inform all healthcare providers you are taking this medication, especially before surgery or dental procedures.,Do not stop abruptly without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LOVENOX (PRESERVATIVE FREE) vs ENOXAPARIN SODIUM (PRESERVATIVE FREE), answered by our medical review team.
LOVENOX (PRESERVATIVE FREE) is a Low Molecular Weight Heparin that works by Low molecular weight heparin (LMWH) that potentiates antithrombin III, accelerating inactivation of factor Xa and thrombin.. ENOXAPARIN SODIUM (PRESERVATIVE FREE) is a Low Molecular Weight Heparin that works by Enoxaparin binds to antithrombin III (ATIII), accelerating its inhibition of coagulation factors Xa and IIa (thrombin). Its anti-factor Xa to anti-factor IIa activity ratio is approximately 3.6:1.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LOVENOX (PRESERVATIVE FREE) and ENOXAPARIN SODIUM (PRESERVATIVE FREE) depend on the specific clinical indication. These are both Low Molecular Weight Heparin agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LOVENOX (PRESERVATIVE FREE) is: 1 mg/kg subcutaneously every 12 hours or 1.5 mg/kg subcutaneously once daily.. The standard adult dose of ENOXAPARIN SODIUM (PRESERVATIVE FREE) is: 1 mg/kg subcutaneously every 12 hours or 1.5 mg/kg subcutaneously once daily. For prophylaxis: 40 mg subcutaneously once daily or 30 mg subcutaneously every 12 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LOVENOX (PRESERVATIVE FREE) and ENOXAPARIN SODIUM (PRESERVATIVE FREE) in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LOVENOX (PRESERVATIVE FREE) is classified as Category C. Low risk of teratogenicity; enoxaparin does not cross the placenta and is not associated with fetal malformations. In the first trimester, risk of teratogenicity is minimal but con. ENOXAPARIN SODIUM (PRESERVATIVE FREE) is classified as Category A/B. Enoxaparin does not cross the placenta and is considered low risk for teratogenicity. No increased risk of congenital anomalies has been reported in humans. First trimester: no kno. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.